Patent ID: 8349558

Claim:
A method for identifying the preferential target antigens of anti-tumoural T-cells of at least one tumour patient that is suffering from a specific tumour comprising: a) providing T cells from the blood of said at least one tumour patient, wherein the T cells are not stimulated by contact with a tumour cell line in vitro; b) providing a panel of transfected dendritic cells (DCs) and/or a panel of transfected B-lymphocytes (BLCs) for said at least one tumour patient, wherein said panel of DCs and/or BLCs are autologous DCs or autologous BLCs transfected with mRNA encoding individual T-cell tumour antigens associated with said specific tumour, wherein multiple T cell tumour antigens are represented within the panel, and wherein said mRNA is provided independent from the extraction of tumour cells from said at least one tumour patient; c) contacting the panel of transfected dendritic cells (DCs) and/or transfected B-lymphocytes (BLCs) for said at least one tumour patient with the respective autologous T cells; and d) identifying the tumour-associated antigens (TAAs) that are recognized by the T cells on the panel of transfected DCs and/or BLCs for said at least one tumour patient.